Pfizer presents promising data from next generation ALK/ROS1 inhibitor in advanced non-small cell lung cancer
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) today announced encouraging new data from a Phase 1/2 study of lorlatinib, the proposed generic name for PF-06463922, Pfizer's investigational, next-generation ALK/ROS1 tyrosine kinase inhibitor. The study showed clinical response in patients with ALK-positive or ROS1-positive advanced non-small cell lung cancer (NSCLC), including patients with brain metastases.
AstraZeneca licenses Zurampic to Grünenthal GmbH in Europe and Latin America
- Details
- Category: AstraZeneca
AstraZeneca today announced that it has entered into a licensing agreement with Grünenthal GmbH for the exclusive rights to Zurampic (lesinurad) in Europe and Latin America. Zurampic was approved by the European Medicines Agency (EMA) in February 2016, in combination with a xanthine oxidase inhibitor (XOI), for the adjunctive treatment of hyperuricemia (excess of uric acid in the blood) in adult patients with uncontrolled gout.
Boehringer Ingelheim increases access to the medication for the treatment of HIV/AIDS
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim is announcing an expansion of its Intellectual Property (IP) enforcement policy. The IP enforcement policy had already been amended in 2007 by an easy-to-use, non-assert declaration for Viramune® (nevirapine).
Novartis highlights its strong foundation for long-term, sustainable growth
- Details
- Category: Novartis
Today Novartis holds its third annual Meet Novartis Management event at its headquarters in Basel, Switzerland, giving investors and analysts the opportunity to meet with more than 20 top executives from Novartis Group, divisions and research.
Boehringer Ingelheim and BioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and BioMed X announced today that they have established a new research team of outstanding scientists from around the world that will conduct research to identify novel approaches for the treatment of patients with psychiatric diseases.
AstraZeneca highlights continued progress of oncology pipeline at ASCO 2016
- Details
- Category: AstraZeneca
AstraZeneca and its global biologics research and development arm, MedImmune, will provide an update on their extensive oncology pipeline at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA, on 3-7 June 2016.
Merck and Pfizer to present Avelumab data in seven different cancers at ASCO annual meeting
- Details
- Category: Pfizer
Merck and Pfizer today announced that avelumab* presentations across seven different tumor types, including two oral presentations, will be featured at the 52nd American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2016, in Chicago, IL.
More Pharma News ...
- Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis
- Johnson & Johnson announces collaboration with HP Inc. subsidiary to create personalized health care solutions with 3D printing technologies
- Novartis Foundation and partners launch innovative hypertension program in Vietnam
- Pfizer awards more than $1 million in metastatic breast cancer research funding
- Selumetinib granted Orphan Drug Designation in the US for adjuvant treatment of differentiated thyroid cancer
- Grants4Apps Accelerator 2016: You imagine, Bayer supports
- AstraZeneca completes acquisition of Takeda's respiratory business